Loading
In the first randomised trial in these rare tumours, sunitinib kept 36 percent of patients free of progression at one year against 19 percent on placebo.
Academic, multicentre, double-blind, placebo-controlled phase 2 trial at 14 European centres: 78 adults with progressive metastatic phaeochromocytoma or paraganglioma were randomised to sunitinib 37.5 mg daily or placebo. The primary endpoint was progression-free survival at 12 months.
14 of 39 sunitinib patients (36 percent) and 7 of 39 placebo patients (19 percent) were progression-free at 12 months, meeting the primary endpoint. Grade 3 or 4 asthenia (18 against 3 percent) and hypertension (13 against 10 percent) were the common toxicities; one death from rectal bleeding was drug-related.
Sunitinib has the highest level of evidence of any drug for progressive metastatic phaeochromocytoma and paraganglioma, alongside the later approval of belzutifan.
Shares Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).
Shares Sunitinib, The Lancet.
Shares Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).
Shares Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).
Shares Sunitinib, The Lancet.
Shares Sunitinib, The Lancet.
Shares Metastatic pheochromocytoma and paraganglioma, Sunitinib.
Shares Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).